Akèy › Kansè nan tete › Kansas
Etid klinik pou Kansè nan tete nan Kansas
26 etid pou Kansè nan tete ap chèche patisipan nan sit nan Kansas.
Vil nan Kansas
Tèks ofisyèl etid la (Anglè)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Veteran Administration Eastern Kansas Healthcare, Leavenworth
- ak 4 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- The University of Kansas Cancer Center, Westwood
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06377852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Cancer Center of Kansas, Wichita
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Kansas Hospital-Cancer Center, Fairway
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- University of Kansas Cancer Center, Westwood
- Cancer Center of Kansas, Wichita
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- HaysMed, Hays
- ak 10 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- AMR Kansas City Oncology, Kansas City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Hays Medical Center Dreiling-Schmidt Cancer Institute, Hays
- KCCC West, Kansas City
- KCCC Overland Park, Overland Park
- ak 3 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Aug 18, 2026 · NCT02302742Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06500481Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- University of Kansas Medical Center, Fairway
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06263543Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- University of Kansas Cancer Center, Kansas City
Ap rekriteFaz 2Volontè an sante akeyi
Laj 45 a 74 · Fanm · Mizajou Aug 4, 2026 · NCT06195306Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Kansas Medical Center (KUMC), Westwood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka
Ap rekriteFaz 3
Laj 18 a 50 · Tout sèks · Mizajou Aug 4, 2026 · NCT06748222Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
- University of Kansas Cancer Center, Kansas City
Ap rekriteFaz 2
Laj 18 a 55 · Fanm · Mizajou Jul 27, 2026 · NCT06184750HER2-positive Breast Cancer Registry
- The University of Kansas Cancer Center, Westwood
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 17, 2026 · NCT06603597Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
- University of Kansas Cancer Center, Kansas City
Ap rekriteFaz 2
Laj 35 ak plis · Fanm · Mizajou Jul 7, 2026 · NCT05941520Integrated Cancer Repository for Cancer Research
- Saint Luke's Cancer Instititute - South, Overland Park
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- The University of Kansas Cancer Center, Westwood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT06757634Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
- The University of Kansas Cancer Center (KUCC), Fairway
- The University of Kansas Cancer Center - Westwood, Kansas City
- KUCC - Indian Creek, Overland Park
- ak 3 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07220135De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of Kansas Cancer Center, Kansas City
- The University of Kansas Cancer Center - Olathe, Olathe
- University of Kansas Cancer Center-Overland Park, Overland Park
- ak 8 plis
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- The University of Kansas Cancer Center, Westwood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT06374459Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- HaysMed, Hays
- Lawrence Memorial Hospital, Lawrence
- The University of Kansas Cancer Center - Olathe, Olathe
- ak 6 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- University of Kansas Cancer Center, Westwood
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT06401421Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
- Cancer Center of Kansas, Wichita
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Nov 10, 2025 · NCT04553770High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
- University of Kansas Medical Center, Kansas City
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 30 a 65 · Fanm · Mizajou Oct 29, 2025 · NCT00291096S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- HaysMed University of Kansas Health System, Hays
- University of Kansas Cancer Center-West, Kansas City
- University of Kansas Cancer Center, Kansas City
- ak 5 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.